Genetic Polymorphism and Toxicology—With Emphasis on Cytochrome P450

Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events

(2010) Klaus A. Tiroch et al.   AMERICAN HEART JOURNAL

Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement

(2010) Dirk Sibbing et al.   CIRCULATION

Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing

(2010) P Lenzini et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

OPRM1 and CYP2B6 Gene Variants as Risk Factors in Methadone-Related Deaths

(2010) H Bunten et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Humanized UGT1 Mouse Model Expressing the UGT1A1*28 Allele for Assessing Drug Clearance by UGT1A1-Dependent Glucuronidation

(2010) H. Cai et al.   DRUG METABOLISM AND DISPOSITION

A role for the pregnane X receptor in flucloxacillin-induced liver injury

(2010) Elise Andrews et al.   HEPATOLOGY

Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI

(2010) Jessica L. Mega et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis

(2010) Jessica L Mega et al.   LANCET

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

(2010) Lars Wallentin et al.   LANCET

A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury

(2010) Jonathan B Singer et al.   NATURE GENETICS

Sequence variants at CHRNB3–CHRNA6 and CYP2A6 affect smoking behavior

(2010) Thorgeir E Thorgeirsson et al.   NATURE GENETICS

Pharmacogenetics of drug hypersensitivity

(2010) Elizabeth J Phillips et al.   PHARMACOGENOMICS

Drug-induced liver injury: past, present and future

(2010) Ann K Daly   PHARMACOGENOMICS

Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future

(2010) Ana Alfirevic et al.   PHARMACOGENOMICS

Personalized therapy in pain management: where do we stand?

(2010) Ulrike M Stamer et al.   PHARMACOGENOMICS

High Frequency of Occurrence of CYP2D6 Gene Duplication/Multiduplication Indicating Ultrarapid Metabolism Among Suicide Cases

(2009) A L Zackrisson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of genetic factors on opioid action

(2009) Branka Kosarac et al.   Current Opinion in Anesthesiology

Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements

(2009) Janne Cadamuro et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Effects of the CYP2D6 Gene Duplication on the Pharmacokinetics and Pharmacodynamics of Tramadol

(2009) Julia Kirchheiner et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin

(2009) Ann K Daly et al.   NATURE GENETICS

Genetic Association Studies in Drug-Induced Liver Injury

(2009) Ann Daly et al.   SEMINARS IN LIVER DISEASE

Respiratory Depression with Tramadol in a Patient with Renal Impairment and CYP2D6 Gene Duplication

(2008) Ulrike M. Stamer et al.   ANESTHESIA AND ANALGESIA

The largest prospective warfarin-treated cohort supports genetic forecasting

(2008) M. Wadelius et al.   BLOOD

Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis

(2008) Jonatan D. Lindh et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

HLA-B*5701 Screening for Hypersensitivity to Abacavir

(2008) Simon Mallal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use

(2008) Felix W Frueh et al.   PHARMACOTHERAPY